Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Future perspectives for optimizing oral antiplatelet therapy
Autore:
Easton, JD;
Indirizzi:
Brown Univ, Dept Neurol, Providence, RI 02912 USA Brown Univ Providence RI USA 02912 Dept Neurol, Providence, RI 02912 USA
Titolo Testata:
CEREBROVASCULAR DISEASES
, volume: 11, anno: 2001, supplemento:, 2
pagine: 23 - 28
SICI:
1015-9770(2001)11:<23:FPFOOA>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
SECONDARY PREVENTION; ASPIRIN; CLOPIDOGREL; STENT; TRIAL; TICLOPIDINE; ANTICOAGULATION; INHIBITION;
Keywords:
antiplatelet therapy; aspirin; clopidogrel; dipyridamole; glycoprotein IIb/IIIa receptor antagonist;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Easton, JD Rhode Isl Hosp, 110 Lockwood St,Suite 324, Providence, RI 02903USA Rhode Isl Hosp 110 Lockwood St,Suite 324 Providence RI USA 02903
Citazione:
J.D. Easton, "Future perspectives for optimizing oral antiplatelet therapy", CEREB DIS, 11, 2001, pp. 23-28

Abstract

Secondary prevention of stroke and other manifestations of atherothrombosis is essential if the burden of disease associated with these events is to be reduced. Therefore, it is important to identify patients most likely to benefit from antiplatelet therapy. There is a good rationale for combining antiplatelet agents with different modes of action, since different signalling pathways contribute to platelet activation. Based on the promising results obtained with an adenosine diphosphate receptor antagonist-aspirin combination in coronary stenting, several additional trials with clopidogrel plus aspirin are ongoing. They include CURE (Clopidogrel in Unstable angina to prevent Recurrent Events, in unstable angina and non-Q-wave myocardial infarction) and COMMIT tin acute myocardial infarction), which compare clopidogrel with placebo in patients receiving aspirin, and CREDO (Clopidogrel for Reduction of Events During extended Observation), a 1-year treatment follow-up to the clopidogrel arms of the CLASSICS trial (Clopidogrel Aspirin Stent International Cooperative Study). Planned trials with clopidogrel in neurology include SPS3 (Secondary Prevention of Small Subcortical Strokes, inpatients with symptomatic lacunar stroke), and MATCH (Management of Atherothrombosis with Clopidogrel in High-risk patients, in patients with stroke or transient ischaemic attack plus one additional risk factor), which will compare the efficacy of clopidogrel plus aspirin versus clopidogrel in reducing important ischaemic events. Combination therapy with an oral glycoprotein (GP) Ilb/llla receptor antagonist plus aspirin has so far been less promising. Trials of three compounds - orbofiban, xemilofiban and sibrafiban -in combination with aspirin for secondary prevention in cardiac patients have reported increased mortality compared with aspirin alone. A similar effect was seen when sibrafiban monotherapy was compared directly with aspirinalone. Trials of newer oral GP Ilb/llla inhibitors are under way or are planned. The combination of dipyridamole plus aspirin appears to be superior to aspirin alone for the prevention of stroke in patients with stroke or transient ischaemic attack; the effectiveness of this combination is being further investigated in ESPRIT (European/Australian Stroke Prevention in Reversible Ischaemia Trial). Copyright (C) 2001 S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 12:36:47